Desmopressin-induced dog ciliary artery relaxation

European Journal of Pharmacology

Volumn 344, Issue 2-3, 1998, Pages 197-201

  Toda, Megumi ^a   Ayajiki, Kazuhide ^a   Okamura, Tomio ^a   Azuma, Ikuo ^b   Toda, Noboru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Ciliary artery; Desmopressin; Endothelium; Nitric oxide (NO); Vasopressin V1 receptor

Indexed keywords

ARGININE; ARGIPRESSIN; DESMOPRESSIN; N(G) NITROARGININE; NITRIC OXIDE; PROSTAGLANDIN F2 ALPHA; RECEPTOR SUBTYPE; RELCOVAPTAN; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; CILIARY ARTERY; DOG; DRUG ANTAGONISM; DRUG INHIBITION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CILIARY ARTERIES; DEAMINO ARGININE VASOPRESSIN; DOGS; FEMALE; MALE; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, VASOPRESSIN; VASODILATION;

EID: 0032485393     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01600-2     Document Type: Article

References (27)

1. 2 vasopressin-receptor-mediated renal vasodilation. J. Cardiovasc. Pharmacol. 23, 331-336.
2. Cosentino, F., Sill, J.C., Katusic, Z.S., 1993. Endothelial L-arginine pathway and relaxations to vasopressin in canine basilar artery. Am. J. Physiol. 264, H413-H418.
3. Edwards, R.M., Trizna, W., Kinter, L.B., 1989. Renal microvascular effects of vasopressin and vasopressin antagonists. Am. J. Physiol. 256, F274-F278.
4. Garcia-Villalon, A.L., Garcia, J.L., Fernandez, N., Monge, L., Gomez, B., Dieguez, G., 1996. Regional differences in the arterial response to vasopressin: role of endothelial nitric oxide. Br. J. Pharmacol. 118, 1848-1854.
5. 2 receptor. J. Clin. Invest. 84, 418-426.
6. Hruby, V.J., Chow, M.S., 1990. Conformational and structural considerations in oxytocin-receptor binding and biological activity. Annu. Res. Pharmacol. Toxicol. 30, 501-534.
7. Katusic, Z.S., Shepherd, J.T., Vanhoutte, P.M., 1984. Vasopressin causes endothelium-dependent relaxations of the canine basilar artery. Circ. Res. 55, 575-579.
8. Kitamura, Y., Okamura, T., Kani, K., Toda, N., 1993. Nitric oxide-mediated retinal arteriolar and arterial dilatation induced by substance P. Invest. Ophthal. Vis. Sci. 34, 2859-2865.
9. Laszlo, F.A., Laszlo, F., De Wied, D., 1991. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol. Rev. 43, 73-108.
10. 2-induced vasodilatation in dogs. Am. J. Physiol. 266, H99-H106.
11. Lolait, S.J., O'Carroll, A.-M., Brownstein, M.J., 1995. Molecular biology of vasopressin receptors. Ann. N. Y. Acad. Sci. 771, 273-292.
12. Manning, M., Balaspiri, L., Acosta, M., Sawyer, W.H., 1973. Solid phase synthesis of [1-deamino, 4-valine]-8-D-arginine-vasopressin (dVDAVP), a highly potent and specific antidiuretic agent possessing protracted effects. J. Med. Chem. 16, 975-978.
13. Manning, M., Balaspiri, L., Moehring, J., Haldar, H., Sawyer, W.H., 1976. Synthesis and some pharmacological properties of deamino-[4-threonine, 8-D-arginine]vasopressin and deamino[8-arginine]vasopressin, highly potent and specific antidiuretic peptides, and [8-D-arginine]vasopressin and deaminoarginine-vasopressin. J. Med. Chem. 19, 842-845.
14. Martinez, M.C., Aldasoro, M., Vila, J.M., Medina, P., Lluch, S., 1994. Responses to vasopressin and desmopressin of human cerebral arteries. J. Pharmacol. Exp. Ther. 270, 622-627.
15. Meienhofer, J., Trzeciak, A., Havran, R.T., Walter, R., 1970. A solidphase synthesis of [8-arginine]-vasopressin through a crystalline protected nonapeptide intermediate and biological properties of the hormone. J. Am. Chem. Soc. 92, 7199-7202.
16. 2 receptors in conscious dogs. Am. J. Physiol. 265, R934-R942.
17. Ohlstein, E.H., Berkowitz, B.A., 1986. Human vascular vasopressin receptors: Analysis with selective vasopressin receptor antagonists. J. Pharmacol. Exp. Ther. 239, 737-741.
18. Okamura, T., Toda, M., Ayajiki, K., Toda, N., 1997. Receptor subtypes involved in relaxation and contraction by arginine vasopressin in canine isolated short posterior ciliary arteries. J. Vase. Res. In press.
19. Onoue, H., Nakamura, N., Toda, N., 1988. Endothelium-dependent and -independent responses to vasodilators of isolated dog cerebral arteries. Stroke 19, 1388-1394.
20. Onoue, H., Kaito, N., Tomii, M., Tokudome, S., Nakajima, M., Abe, T., 1994. Human basilar and middle cerebral arteries exhibit endothelium-dependent responses to peptides. Am. J. Physiol. 267, H880-H886.
21. Robinson, A.D., 1976. DDAVP in the treatment of central diabetes insipidus. N. Engl. J. Med. 294, 507-511.
22. Rudichenko, V.M., Beierwaltes, W.H., 1995. Arginine vasopressin-induced renal vasodilation mediated by nitric oxide. J. Vase. Res. 32, 100-105.
23. Russ, R.D., Walker, B.R., 1992. Role of nitric oxide in vasopressinergic pulmonary vasodilatation. Am. J. Physiol. 262, H743-H747.
24. 1a receptors. J. Clin. Invest. 92, 224-231.
25. Suzuki, Y., Satoh, S., Oyama, H., Takayasu, M., Shibuya, M., 1993. Regional differences in the vasodilator response to vasopressin in canine cerebral arteries in vivo. Stroke 24, 1049-1054.
26. Zaoral, M., Kolc, J., Sorm, F., 1967. Synthesis of 1-deamino-8-D-g-aminobutyrine-vasopressin, 1-deamino-8-D-lysine-vasopressin, and 1-deamino-8-D-argininevasopressin. Collect. Czech. Chem. Commun. 32, 1250-1257.
27. Zaoral, M., Flegel, M., Barth, T., Machova, A., 1978. Purification of 10 g amounts of [1-β-mercapto-propionic acid, 8-D-arginine] vasopressin (DDAVP) on a continuous free-flow electrophoresis. Chemical and pharmacological data of DDAVP and byproducts. Collect. Czech. Chem. Commun. 43, 511-522.